Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 2Phase 2 1

Status

Completed 4Terminated 2Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1INDIV 1

Study Type

Interventional 7

Sponsor

Cancer Type

Dermatologic 7Other hematologic neoplasm 5Thoracic 3Gynecologic 3Plasma cell 2Myeloid 2Genitourinary 2Gastrointestinal 2Other solid neoplasm 1Lymphoid 1CNS 1Breast 1

Conditions

Melanoma 7Neoplasms 2Skin Neoplasms 1Carcinogenesis 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42Specimen Handling 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Interventional × Monatide (IMS 3015) × Dermatologic × Clear all
NCT03929029 2026-01-05

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
11 enrolled 11 charts
Dermatologic

Melanoma

NCT01810016 2022-10-12

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Ludwig Institute for Cancer Research

Phase 1 Terminated
8 enrolled 16 charts
Dermatologic

Melanoma, Neoplasms

NCT00112242 2020-06-18

Immunotherapy of Stage III/IV Melanoma Patients

Centre Hospitalier Universitaire Vaudois

Phase 1 Completed
39 enrolled 18 charts
Dermatologic

Melanoma

NCT01308294 2020-06-11

LAG-3/IMP321

Centre Hospitalier Universitaire Vaudois

Phase 1/2 Terminated
16 enrolled 12 charts
Dermatologic

Melanoma

NCT01079741 2018-02-13

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
34 enrolled 10 charts
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms, Carcinogenesis

NCT00124124 2015-02-13

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

Bhardwaj, Nina, M.D.

Phase 1 Completed
50 enrolled
Dermatologic

Melanoma

NCT00651703 2010-11-15

Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients

Cytos Biotechnology AG

Phase 2 Completed
21 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡